The startup is a clinical-stage biotechnology company focused on developing proprietary nanocarriers for targeted chemotherapy, enabling precise delivery of therapeutic agents to cancer cells. Its nanomedicine pipeline includes programs at various stages of preclinical and clinical development, aimed at improving treatment efficacy and minimizing side effects for cancer patients.
Funding
$14.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
GPFounders
Product
Problem
Traditional chemotherapy often lacks precision, leading to systemic toxicity and reduced efficacy due to off-target effects on healthy cells. This can result in significant side effects and limit the maximum tolerated dose, hindering optimal treatment outcomes for cancer patients.
Solution
RS Research is developing smart nanomedicines that leverage proprietary nanocarriers for targeted drug delivery, enhancing chemotherapeutic efficacy while minimizing systemic toxicity. Their Sagitta® platform utilizes biodegradable conjugation to create nanocarriers that selectively target cancer cells, improving the therapeutic index and pharmacokinetic profile of chemotherapeutic agents. By precisely delivering drugs to the tumor microenvironment, RS Research aims to reduce off-target effects, improve patient tolerability, and ultimately achieve better clinical outcomes. The Sagitta® platform is designed for versatility, accommodating a range of targeting ligands, monoclonal antibodies, and drug payloads.
Target Audience
The primary target audience includes oncology researchers and clinicians seeking to improve the efficacy and reduce the toxicity of chemotherapy, as well as pharmaceutical companies looking for innovative drug delivery platforms for cancer therapeutics.
Features
- Sagitta® Bir and Sagitta® Dui: Biodegradable conjugation platforms designed for optimal therapeutic index, pharmacokinetics, and manufacturability.
- Dual drug loading capacity for synergistic therapeutic effects.
- Compatibility with a wide range of targeting ligands and monoclonal antibodies for enhanced specificity.
- GMP-certified manufacturing facility for clinical batch production of lyophilized oncology drugs.
- Improved pharmacokinetic profile, prolonging circulation time compared to native APIs.
- Enhanced Permeability and Retention (EPR) effect for higher drug accumulation in tumors.
- Selective and biologic stimuli-driven drug release mechanisms.